Copyright: Jacobio Pharmaceuticals Co., Ltd.   Beijing ICP preparation 17065868-1   



Address: Building F2, No. 88, Kechuang 6th Street, Beijing Economic Development Zone

Tel: +86  010-56315466

Fax: +86  010-56315314




Page view:

  Jacobio’s leading drug candidate, JAB-3068, a SHP2 inhibitor, is being evaluated in phase IIa clinical trials for the treatment of patients with solid tumors. It has been granted orphan drug designation (ODD) from FDA for the treatment of patients with esophageal cancer. On July 3, 2019, Jacobio’s JAB-3312, an oral small-molecule anti-tumor agent, has been approved for clinical study by FDA.